Siemens Healthineers Faces a Perfect Storm as Basel Conference Opens Against a Backdrop of Debt and Declining Shares

The irony could hardly be starker. As Siemens Healthineers kicks off the ECIO oncology conference in Basel today, showcasing the future of image-guided cancer therapy, its stock is languishing dangerously close to a 52-week low. The shares closed Friday at €35.75, a whisker above the year’s trough of €35.66, and have shed nearly 20% since January.

The technical picture is bleak. The relative strength index has plunged to 25.5 — deep in oversold territory — and an algorithmic rating service downgraded the stock over the weekend. The gap to the 200-day moving average is widening by the session, leaving chartists with little to cling to beyond that single support line at the yearly low.

A Trio of Troubles

Three distinct headwinds are converging on the medical technology group. First, the German government’s planned savings package for statutory health insurance (GKV) is set for a decision on Wednesday. State-imposed cuts to healthcare spending could crimp demand for expensive diagnostic equipment, injecting a fresh dose of political uncertainty into an already nervous market.

Second, the US tariff regime is taking a direct toll. New American duties are expected to shave roughly €400 million off adjusted EBIT this year, while adverse currency effects are eating another €200 million to €250 million into operating profit. Management is nonetheless holding its full-year guidance: comparable revenue growth of 5% to 6% and adjusted earnings per share between €2.20 and €2.40.

Third, and perhaps most daunting, is the €13.9 billion debt pile that Siemens Healthineers will have to shoulder alone once it separates from parent Siemens. The spin-off timeline is firming up — Siemens aims to have the decision ready for its annual general meeting in February 2027, distributing 30% of its Healthineers stake directly to its own shareholders and reducing its holding from roughly 67% to below 20%. But how the company intends to refinance that mountain of liabilities without the parental guarantee remains an open question.

Should investors sell immediately? Or is it worth buying Siemens Healthineers?

Diagnostics Drag and China Complications

The operational picture offers little comfort. First-quarter revenue edged up 3.8%, but adjusted earnings per share slipped 3% to €0.49. The diagnostics division was the culprit, with sales falling 3% as an anti-corruption campaign in China and centralized procurement processes there weighed heavily on the business.

Analysts are bracing for more of the same when second-quarter results land on May 7. The consensus calls for EPS of €0.51, down from €0.56 a year earlier, with revenue essentially flat at just over €5.9 billion.

Waiting for Catalysts

The oncology conference in Basel represents a genuine operational bright spot. Siemens Healthineers’ advanced therapies division, which focuses on interventional oncology, has been a growth driver, and investors are hoping the ECIO gathering will generate fresh momentum in order intake. The company’s push into image-guided cancer treatment is a credible long-term story.

Yet the market is focused on nearer-term questions. Can the diagnostics business stabilize in China? Will management present a concrete refinancing plan for the post-spin-off balance sheet? Without affirmative answers to both, the stock’s distance from that 200-day moving average of nearly €44 is unlikely to shrink.

Analysts remain broadly constructive on the long view. RBC Capital Markets sees a price target of €55.00, Goldman Sachs pegs fair value at €45.00, and the broader consensus sits around €53. But with the stock trading at roughly two-thirds of those levels, the market is pricing in a lot of bad news — and demanding proof that the company can navigate its way out of this multi-front storm.